Vaxart, Inc. (VXRT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 73.11M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 11.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $73.11M | (m) | (m) | $11.00K | (m) | (m) |
| 2026-03-31 | (m) | $76.84M | (m) | (m) | $7.14M | (m) | (m) |
| 2025-12-31 | (m) | $86.75M | (m) | (m) | $14.56M | (m) | (m) |
| 2025-09-30 | (m) | $169.30M | (m) | (m) | $42.72M | (m) | (m) |
| 2025-06-30 | (m) | $117.88M | (m) | (m) | $4.28M | (m) | (m) |
| 2025-03-31 | (m) | $98.50M | (m) | (m) | $1.50M | (m) | (m) |
| 2024-12-31 | (m) | $90.88M | (m) | (m) | $5.76M | (m) | (m) |
| 2024-09-30 | (m) | $80.36M | $22.04M | (m) | $591.00K | (m) | (m) |
| 2024-06-30 | (m) | $15.76M | (m) | (m) | $1.09M | (m) | (m) |
| 2024-03-31 | (m) | $14.12M | $26.73M | (m) | $556.00K | (m) | (m) |
| 2023-12-31 | (m) | $13.72M | $34.76M | (m) | $3.01M | (m) | (m) |
| 2023-09-30 | (m) | $11.27M | (m) | (m) | $424.00K | (m) | (m) |
| 2023-06-30 | (m) | $13.88M | (m) | (m) | $29.00K | (m) | (m) |
| 2023-03-31 | (m) | $15.68M | (m) | (m) | $264.00K | (m) | (m) |
| 2022-12-31 | (m) | $17.92M | $44.01M | (m) | $20.00K | (m) | (m) |
| 2022-09-30 | (m) | $21.74M | (m) | (m) | $0.00 | (m) | (m) |
| 2022-06-30 | (m) | $15.93M | (m) | (m) | $0.00 | (m) | (m) |
| 2022-03-31 | (m) | $11.04M | (m) | (m) | $81.00K | (m) | (m) |
| 2021-12-31 | (m) | $10.78M | (m) | (m) | $71.00K | (m) | (m) |
| 2021-09-30 | (m) | $12.60M | (m) | (m) | $190.00K | (m) | (m) |
| 2021-06-30 | (m) | $12.78M | (m) | (m) | $107.00K | (m) | (m) |
| 2021-03-31 | (m) | $11.64M | (m) | (m) | $700.00K | (m) | (m) |
| 2020-12-31 | (m) | $11.76M | (m) | (m) | $334.00K | (m) | (m) |
| 2020-09-30 | (m) | $10.30M | (m) | (m) | $250.00K | (m) | (m) |
| 2020-06-30 | (m) | $11.50M | (m) | (m) | $227.00K | (m) | (m) |
| 2020-03-31 | (m) | $7.44M | (m) | (m) | $2.66M | (m) | (m) |
| 2019-12-31 | (m) | $9.17M | (m) | (m) | $3.62M | (m) | (m) |
| 2019-09-30 | (m) | $9.15M | $19.60M | (m) | $559.00K | (m) | (m) |
| 2019-06-30 | (m) | $7.48M | $16.30M | (m) | $35.00K | (m) | (m) |
| 2019-03-31 | (m) | $8.55M | $8.40M | (m) | $5.58M | (m) | (m) |
| 2018-12-31 | (m) | $7.47M | $11.51M | (m) | $1.80M | (m) | (m) |
| 2018-09-30 | (m) | $8.03M | $17.92M | (m) | $256.00K | (m) | (m) |
| 2018-06-30 | (m) | $8.79M | $23.92M | (m) | $561.00K | (m) | (m) |
| 2018-03-31 | (m) | $7.80M | $17.50M | (m) | $13.35M | (m) | (m) |
| 2017-12-31 | $50.60M | $5.70M | $29.40M | $18.70M | $2.50M | (m) | 8.88× |
| 2017-09-30 | $51.20M | $5.20M | $19.60M | $31.50M | $100.00K | (m) | 9.85× |
| 2017-06-30 | $50.10M | $5.90M | $17.70M | $31.80M | $600.00K | (m) | 8.49× |
| 2017-03-31 | $51.60M | $5.50M | $11.80M | $33.20M | $6.60M | (m) | 9.38× |
| 2016-12-31 | $64.10M | $10.50M | $38.10M | $21.80M | $4.20M | (m) | 6.10× |
| 2016-09-30 | (m) | $8.80M | $45.90M | $21.80M | (m) | (m) | (m) |
| 2016-06-30 | $71.20M | $9.20M | $49.70M | $20.80M | $700.00K | (m) | 7.74× |
| 2016-03-31 | $86.30M | $8.70M | $30.60M | $45.60M | $10.10M | (m) | 9.92× |
| 2015-12-31 | (m) | $6.00M | $39.00M | (m) | $5.10M | (m) | (m) |
| 2015-09-30 | $75.60M | $6.70M | $45.30M | $27.10M | $3.20M | (m) | 11.28× |
| 2015-06-30 | $84.40M | $9.00M | $44.70M | $27.10M | $12.60M | (m) | 9.38× |
| 2015-03-31 | $105.70M | $7.20M | $61.50M | $34.10M | $10.10M | (m) | 14.68× |
| 2014-12-31 | (m) | $10.90M | $63.70M | $39.80M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $19.30M | $57.70M | $43.30M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $26.90M | $81.70M | (m) | $18.70M | (m) | (m) |
| 2014-03-31 | (m) | $24.30M | $80.10M | (m) | $36.50M | (m) | (m) |
| 2013-12-31 | (m) | $18.30M | $51.40M | (m) | $26.90M | (m) | (m) |
| 2013-09-30 | (m) | $13.80M | $60.80M | (m) | $12.90M | (m) | (m) |
| 2013-06-30 | (m) | $15.90M | $66.80M | (m) | $11.00M | (m) | (m) |
| 2013-03-31 | (m) | $14.44M | $70.27M | (m) | $15.17M | (m) | (m) |
| 2012-12-31 | (m) | $16.95M | $74.11M | (m) | $11.38M | (m) | (m) |
| 2012-09-30 | (m) | $5.59M | $66.32M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $4.04M | $92.65M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $3.62M | $94.88M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $6.25M | $94.31M | $2.08M | (m) | (m) | (m) |
| 2011-09-24 | (m) | $9.89M | $92.95M | $9.06M | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $74.18M | (m) | (m) | (m) | (m) |
| 2011-06-25 | (m) | $11.54M | $86.62M | $15.71M | (m) | (m) | (m) |
| 2011-03-26 | (m) | (m) | $59.09M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $53.56M | (m) | (m) | (m) | (m) |
| 2010-12-25 | (m) | $17.93M | $53.56M | $54.60M | (m) | (m) | (m) |
| 2010-09-25 | (m) | (m) | $37.28M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $89.80M | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | $32.45M | (m) | (m) | (m) | (m) |
| 2009-12-26 | (m) | (m) | $59.51M | (m) | (m) | (m) | (m) |
| 2008-12-27 | (m) | (m) | $106.44M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |